CRISPR Therapeutics(US:CRSP) Financial Modeling Prep·2026-01-23 04:00Core Insights - CRISPR Therapeutics AG is a leading biotechnology company specializing in CRISPR/Cas9 gene-editing technology aimed at treating various genetic diseases [1] - The company faces competition from other biotech firms such as Editas Medicine and Intellia Therapeutics in the gene-editing sector [1] Stock Performance - Recently, CRSP's stock closed at $54.21, reflecting a 4.71% decline from the previous day, contrasting with gains in the broader market [2][6] - Prior to the latest trading session, CRSP's stock had increased by 3.93%, outperforming the Medical sector's 0.92% gain and the S&P 500's 1.57% increase [3] - Over the past month, CRSP's stock fell by 2.91%, underperforming the Medical sector's 2.08% gain and the S&P 500's 1.15% rise [3] Financial Metrics - The upcoming earnings report is expected to show an EPS of -$1.15, a 161.36% decrease from the previous year, and revenue anticipated at $4 million, marking an 88.78% decline [4] - For the full year, earnings are projected at -$6.33 per share, with revenue of $8.54 million [4] - CRSP has a negative P/E ratio of -11.37, indicating unprofitability, and a high price-to-sales ratio of 157.68, suggesting a premium for each sales dollar [5] - The company maintains a low debt-to-equity ratio of 0.11 and a strong current ratio of 16.22, reflecting a conservative capital structure and robust liquidity [5]